RecruitingPhase 4NCT06801249
Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome
Studying Adrenal Cushing syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Principal Investigator
- Guido Di Dalmazi, MD, M.DIRCCS Azienda Ospedaliero-Universitaria di Bologna
- Intervention
- Metarapone(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2021 – 2025
Study locations (3)
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- Azienda Ospedaliera Universitaria Federico II, Naples, Italy
- Azienda Ospedale-Università Padova, Padua, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06801249 on ClinicalTrials.govOther trials for Adrenal Cushing syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07168122Establishment and Clinical Application of Reference Intervals of Salivary CortisolShanghai 6th People's Hospital
- RECRUITINGNANCT06250699A Single Center Randomized Controlled Study on the Promotion of Rapid RecoveryZhe Meng
- RECRUITINGNANCT05911620Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous HypercorticismCentral Hospital, Nancy, France
- RECRUITINGNANCT05881005NAC- NAFLD and CushingUniversity Hospital, Angers
- RECRUITINGNCT06050057Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted AdrenalectomyUniversity Hospital Olomouc
- RECRUITINGNCT05521529Cushing's Syndrome Before and After Treatment (CORRECT)University of Aarhus
- ACTIVE NOT RECRUITINGNCT05446779Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden DeathHelsinki University Central Hospital
- RECRUITINGPHASE2NCT03708900Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's SyndromeRECORDATI GROUP